Beta-Blockers: Classification, Pharmacology of Propranolol

Classification of Beta-Blockers

Generation 1 - Non-selective (β1 + β2 blockade)

Generation 2 - Cardioselective (β1-selective)

Generation 3 - Mixed α + β Blockade

Additional Sub-classification by Properties

Propranolol - Detailed Pharmacology

Mechanism of Action (MoA)

1. Competitive antagonism at β-adrenoceptors: Propranolol competes with catecholamines (epinephrine, norepinephrine) for β1 and β2 receptor binding sites. Being a reversible competitive antagonist, its blockade can be overcome by sufficiently high agonist concentrations.
2. β1 receptor blockade (cardiac): Blocks β1 receptors on the sinoatrial (SA) node, atrioventricular (AV) node, and myocardium, reducing cyclic AMP-mediated stimulation of cardiac pacemaker activity, conduction velocity, and contractility.
3. β2 receptor blockade (peripheral/pulmonary): Blocks β2 receptors in bronchial smooth muscle (causing bronchoconstriction), vascular smooth muscle, uterus, and liver/skeletal muscle (inhibiting glycogenolysis and gluconeogenesis).
4. Membrane Stabilizing Activity (MSA) / Local Anesthetic effect: At high concentrations, propranolol stabilizes the neuronal membrane by reducing Na+ conductance (quinidine-like effect). This is clinically relevant only at toxic doses, not at therapeutic concentrations.
5. Reduction of plasma renin: Propranolol reduces renin secretion from juxtaglomerular cells (which are innervated by β1 receptors), contributing to its antihypertensive effect.
6. Central effects: Being highly lipophilic, propranolol crosses the blood-brain barrier and reduces central sympathetic outflow, contributing to its antihypertensive and anxiolytic effects.

As stated in Katzung: "At sufficiently high plasma concentrations, propranolol also has local anesthetic properties. This is the result of inhibition of sodium ion channels and is not related to β-receptor blockade... The clinical relevance of membrane-stabilizing activity of beta blockers is uncertain, but it may be important in the treatment of patients with digitalis intoxication or arrhythmias related to excessive membrane excitability." - Katzung's Basic and Clinical Pharmacology, 16th Edition

Pharmacological Actions

1. Cardiovascular System

• Negative chronotrope: Reduces heart rate (resting and exercise-induced tachycardia) by blocking β1 receptors at the SA node
• Negative inotrope: Reduces force of myocardial contraction by blocking β1 receptors on ventricular myocardium
• Negative dromotropy: Slows AV nodal conduction, increases PR interval, prolongs effective refractory period of AV node
• Reduced cardiac output: Result of decreased HR and contractility
• Anti-ischemic: Reduces myocardial oxygen demand by reducing HR and contractility; prolongs diastolic filling time improving coronary perfusion

• Initially, blockade of β2 receptors (which normally mediate vasodilation) causes an increase in peripheral vascular resistance
• With chronic use, peripheral vascular resistance returns toward normal due to resetting of baroreceptors
• β2 blockade in the kidney reduces renin release, thereby reducing angiotensin II and aldosterone, contributing to long-term blood pressure lowering

• In hypertensive patients, chronic propranolol use lowers blood pressure
• Mechanism: Reduction in cardiac output + decreased renin secretion + central sympatholysis

2. Respiratory System

• Bronchoconstriction via β2 blockade in bronchial smooth muscle
• Increases airway resistance - particularly dangerous in asthmatics and COPD patients
• This is mediated by β2 blockade and is absent/minimal with β1-selective agents

3. CNS

• Due to high lipophilicity, propranolol crosses BBB
• Reduces anxiety (especially performance anxiety/somatic symptoms of tremor, palpitations, sweating)
• Causes fatigue, sleep disturbances, nightmares, and rarely depression
• Used in migraine prophylaxis and essential tremor (exact CNS mechanism unclear)

4. Metabolic Effects

• Inhibits glycogenolysis and gluconeogenesis via β2 blockade in the liver and skeletal muscle
• Masks tachycardia (a key warning sign of hypoglycemia) - dangerous in insulin-dependent diabetics
• Can prolong hypoglycaemic episodes
• Increases LDL and triglycerides; decreases HDL - unfavorable lipid profile

5. Eye

• Reduces intraocular pressure by decreasing aqueous humor production (used topically as timolol for glaucoma)

6. Uterus

• β2 blockade can reduce uterine relaxation (β2 agonists like ritodrine relax the uterus)

Therapeutic Uses

1. Hypertension

• One of the first-line agents in managing essential hypertension, especially in younger patients or those with co-existing cardiac disease
• Works by decreasing cardiac output and inhibiting renin secretion

2. Angina Pectoris

• Reduces myocardial oxygen demand by lowering HR, contractility, and blood pressure
• Effective in stable (effort) angina; first-line along with nitrates

3. Cardiac Arrhythmias

• Useful in supraventricular arrhythmias: atrial fibrillation/flutter (rate control), AVNRT, paroxysmal SVT
• Effective in ventricular arrhythmias induced by sympathetic stimulation (exercise-induced VT, digitalis toxicity arrhythmias, post-MI VF prophylaxis)
• Used in pheochromocytoma (only after alpha-blockade is established first, to prevent hypertensive crisis)
• Reduces AV nodal conduction - prolongs PR interval

4. Heart Failure (with caution)

• Paradoxically beneficial in chronic stable heart failure (particularly HFrEF)
• Reduces mortality and hospitalizations; used as metoprolol succinate or carvedilol (more commonly), or bisoprolol - not propranolol specifically
• Must be started at low dose and titrated slowly; must NOT be used in acute decompensated heart failure

5. Myocardial Infarction (Post-MI)

• Reduces mortality and re-infarction after MI
• Anti-arrhythmic and anti-ischemic properties are beneficial
• IV use in early MI is now discouraged; oral use within 24 hrs without contraindications is class I recommendation (ACC/AHA)

6. Thyrotoxicosis (Hyperthyroidism)

• Propranolol controls the sympathomimetic manifestations of thyrotoxicosis: tachycardia, tremor, anxiety, sweating, palpitations
• Also reduces peripheral conversion of T4 to T3
• Used as adjunctive therapy in thyroid storm

7. Migraine Prophylaxis

• Reduces frequency and severity of migraines (mechanism not fully understood - possibly serotonergic modulation or CNS effect)
• Approved and commonly used agent

8. Essential Tremor

• Propranolol is first-line for essential tremor
• β2 blockade in skeletal muscle spindles reduces tremor amplitude

9. Performance Anxiety / Social Phobia

• Effective for situational (performance) anxiety - reduces somatic symptoms like palpitations, trembling, sweating
• Katzung: "The use of propranolol for performance anxiety as part of social phobia is the most familiar application of β-adrenergic receptor antagonists in anxiety disorders"

10. Hypertrophic Obstructive Cardiomyopathy (HOCM)

• Reduces outflow tract obstruction and symptoms by slowing HR and decreasing contractility

11. Portal Hypertension

• Reduces portal pressure by lowering cardiac output and causing splanchnic vasoconstriction (via β2 blockade)
• Used in prophylaxis of variceal bleeding

12. Pheochromocytoma

• Always use alpha-blockade first, then add propranolol to control tachycardia
• Using propranolol alone in pheochromocytoma can cause severe hypertensive crisis (unopposed α-adrenergic stimulation)

13. Glaucoma

• Topical beta-blockers (timolol, betaxolol) reduce intraocular pressure by decreasing aqueous humor production

Adverse Effects

Cardiovascular

• Bradycardia (sinus bradycardia, heart block)
• Hypotension
• Heart failure exacerbation: Due to negative inotropic effect; dangerous in patients with compensated HF
• Peripheral vascular disease: Cold extremities, Raynaud's phenomenon (due to reduced cardiac output and β2-mediated vasodilation blockade)
• Rebound hypertension/angina on abrupt withdrawal: Sudden discontinuation after chronic use can precipitate angina, MI, or severe hypertension due to upregulation of β-receptors - always taper gradually

Respiratory

• Bronchoconstriction: Can precipitate fatal bronchospasm in asthmatic patients
• Increases airway resistance; contraindicated in asthma

Metabolic

• Hypoglycaemia prolongation and masking: Especially in insulin-dependent diabetics; masks tachycardia warning sign of hypoglycaemia (sweating is NOT masked)
• Dyslipidaemia: Increases triglycerides, decreases HDL
• Weight gain

CNS

• Fatigue, weakness (most common)
• Sleep disturbances, insomnia, nightmares (more with lipophilic agents like propranolol)
• Depression (rare but documented)
• Cognitive impairment (rare, mainly in elderly)
• Sexual dysfunction (impotence)

Other

• Cold extremities (Raynaud's-like phenomenon)
• GI symptoms: Nausea, diarrhea, constipation
• Alopecia (rare)

Contraindications

• Katzung's Basic and Clinical Pharmacology, 16th Edition - Chapter 10: Adrenoceptor Antagonist Drugs
• Rosen's Emergency Medicine: Concepts and Clinical Practice - Beta-Adrenergic Blockers section
• Berek & Novak's Gynecology - Adrenergic Inhibitors section